ENTA - エナンタ・ファ―マシュ―ティカルズ （Enanta Pharmaceuticals Inc.）

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 at 3:00 p.m. PT. A live webcast of the presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of E

Tarrytown, New York, Nov. 29, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) the largest ENT, Allergy, and Audiology practice in the country is pleased to announce that Daniel Blum, MPA has been appointed as its new Chief Executive Officer, effective February 27, 2023. Daniel Blum will succeed Robert Glazer who is stepping down from the CEO role after 25 years. In support of this significant transition, Robert Glazer will continue to serve as the EVP of QMMS USA, LLC in an advisory capacity through the end of 2023. Steven Gold, MD, Vice President of ENTA and Chair of the ENTA CEO Search Committee commented, "CEO succession planning has been a joint effort between senior management and the Board of Trustees. Dan''s expertise and proven leadership in healthcare matches our vision and makes him the ideal person to lead the company into the future." Dr. Gold further added, "We are confident that Dan will lead our company to new heights based on the strong foundation that Bob Glazer has provided over 25 years.

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) concluded the trading at $41.58 on Friday, November 25, with a fall of -7.60% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $45.00 and 5Y monthly beta was reading 0.61 with its price kept floating in the … Analysts Provide An Important Insights On Enanta Pharmaceuticals Inc. (ENTA) Read More »

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in November: Piper Sandler 34th Annual Healthcare Conference: Fireside Chat at 2:00 p.m. ET on November 29

https://www.investing.com/news/pro/enanta-pharmaceuticals-pt-lowered-to-54-at-rbc-capital-432SI-2949736

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the initiation of a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including the eld

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) shares, rose in value on Friday, 09/16/22, with the stock price down by -3.66% to the previous day’s close as strong demand from buyers drove the stock to $55.80. Actively observing the price movement in the last trading, the stock closed the session at $57.92, falling within a range of $54.10 … Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) Forecast: Expect A -73.84% Drop Within A Few Months Read More »

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral coronavirus protease inhibitor specifically designed for the treatment of COVID-19, will be presented at IDWeek 2022 being held October 19 – 23, 2022 in Washington,

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September: Wells Fargo Healthcare Conference: Presentation at 3:10 p.m. ET on September 8, 2022 Baird Global Healthcare Conference: Fireside Chat at 9:40

https://www.investing.com/news/pro/enanta-pharmaceuticals-pt-raised-to-59-at-oppenheimer-432SI-2868790

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the initiation of a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including the eld

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) shares, rose in value on Friday, 09/16/22, with the stock price down by -3.66% to the previous day’s close as strong demand from buyers drove the stock to $55.80. Actively observing the price movement in the last trading, the stock closed the session at $57.92, falling within a range of $54.10 … Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) Forecast: Expect A -73.84% Drop Within A Few Months Read More »

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral coronavirus protease inhibitor specifically designed for the treatment of COVID-19, will be presented at IDWeek 2022 being held October 19 – 23, 2022 in Washington,

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September: Wells Fargo Healthcare Conference: Presentation at 3:10 p.m. ET on September 8, 2022 Baird Global Healthcare Conference: Fireside Chat at 9:40

https://www.investing.com/news/pro/enanta-pharmaceuticals-pt-raised-to-59-at-oppenheimer-432SI-2868790